{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:21:16Z","timestamp":1777648876043,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12981-018-0216-9","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T05:12:36Z","timestamp":1545369156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Looking at the positives: proactive management of STIs in people with HIV"],"prefix":"10.1186","volume":"15","author":[{"given":"Carole","family":"Khaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Read","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"216_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1128\/CMR.19.1.29-49.2006","volume":"19","author":"RE Lafond","year":"2006","unstructured":"Lafond RE, Lukehart SA. Biological basis for syphilis. Clin Microbiol Rev. 2006;19:29\u201349.","journal-title":"Clin Microbiol Rev"},{"key":"216_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7861\/clinmedicine.3-3-209","volume":"3","author":"D Goldmeier","year":"2003","unstructured":"Goldmeier D, Guallar C. Syphilis: an update. Clin Med. 2003;3:209\u201311.","journal-title":"Clin Med"},{"key":"216_CR3","first-page":"70","volume":"32","author":"LW Harrison","year":"1956","unstructured":"Harrison LW. The Oslo study of untreated syphilis, review and commentary. Br J Vener Dis. 1956;32:70\u20138.","journal-title":"Br J Vener Dis"},{"key":"216_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/archderm.1956.01550050094017","volume":"73","author":"S Olansky","year":"1956","unstructured":"Olansky S, Harris A, Cutler JC, Price EV. Untreated syphilis in the male Negro; twenty-two years of serologic observation in a selected syphilis study group. AMA Arch Dermatol. 1956;73:516\u201322.","journal-title":"AMA Arch Dermatol"},{"key":"216_CR5","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.2105\/AJPH.2013.301520","volume":"103","author":"MA Rodriguez","year":"2013","unstructured":"Rodriguez MA, Garcia R. First, do no harm: the US sexually transmitted disease experiments in Guatemala. Am J Public Health. 2013;103:2122\u20136.","journal-title":"Am J Public Health"},{"key":"216_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00005792-195602000-00002","volume":"35","author":"HJ Magnuson","year":"1956","unstructured":"Magnuson HJ, Thomas EW, Olansky S, Kaplan BI, De Mello L, Cutler JC. Inoculation syphilis in human volunteers. Medicine. 1956;35:33\u201382.","journal-title":"Medicine"},{"key":"216_CR7","first-page":"217","volume":"59","author":"PC Schober","year":"1983","unstructured":"Schober PC, Gabriel G, White P, Felton WF, Thin RN. How infectious is syphilis? Br J Vener Dis. 1983;59:217\u20139.","journal-title":"Br J Vener Dis"},{"key":"216_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1155\/2005\/597580","volume":"16","author":"S Ratnam","year":"2005","unstructured":"Ratnam S. The laboratory diagnosis of syphilis. Can J Infect Dis Med Microbiol. 2005;16:45\u201351.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"216_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1128\/AAC.40.5.1104","volume":"40","author":"M Karlsson","year":"1996","unstructured":"Karlsson M, Hammers S, Nilsson-Ehle I, Malmborg AS, Wretlind B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother. 1996;40:1104\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"216_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1128\/AAC.28.2.347","volume":"28","author":"CW Yim","year":"1985","unstructured":"Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother. 1985;28:347\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"216_CR11","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1086\/500406","volume":"42","author":"KG Ghanem","year":"2006","unstructured":"Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;42:e45\u20139.","journal-title":"Clin Infect Dis"},{"key":"216_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.amjmed.2008.04.042","volume":"121","author":"T Wong","year":"2008","unstructured":"Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline\/tetracycline versus benzathine penicillin. Am J Med. 2008;121:903\u20138.","journal-title":"Am J Med"},{"key":"216_CR13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4269\/ajtmh.15-0316","volume":"93","author":"D Smajs","year":"2015","unstructured":"Smajs D, Pastekova L, Grillova L. Macrolide resistance in the syphilis spirochete, Treponema pallidum ssp. pallidum: can we also expect macrolide-resistant yaws strains? Am J Trop Med Hyg. 2015;93:678\u201383.","journal-title":"Am J Trop Med Hyg"},{"key":"216_CR14","unstructured":"Public Health England. Sexually transmitted infections and chlamydia screening in England, 2016. In: Health protection report, vol. 11; 2017."},{"key":"216_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5694\/j.1326-5377.2005.tb06989.x","volume":"183","author":"F Jin","year":"2005","unstructured":"Jin F, Prestage GP, Kippax SC, Pell CM, Donovan BJ, Kaldor JM, Grulich AE. Australian\u2013Thai HIVVC: epidemic syphilis among homosexually active men in Sydney. Med J Aust. 2005;183:179\u201383.","journal-title":"Med J Aust"},{"key":"216_CR16","first-page":"218","volume":"183","author":"RJ Guy","year":"2005","unstructured":"Guy RJ, Leslie DE, Simpson K, Hatch B, Leydon J, Hellard ME, Kelly HA. Sustained increase in infectious syphilis notifications in Victoria. Med J Aust. 2005;183:218.","journal-title":"Med J Aust"},{"key":"216_CR17","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1086\/513427","volume":"44","author":"NM Zetola","year":"2007","unstructured":"Zetola NM, Klausner JD. Syphilis and HIV infection: an update. Clin Infect Dis. 2007;44:1222\u20138.","journal-title":"Clin Infect Dis"},{"key":"216_CR18","unstructured":"The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. In: Annual surveillance report 2016. UNSW Sydney, Sydney NSW 2052; 2016."},{"key":"216_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00007435-200103000-00007","volume":"28","author":"AM Rompalo","year":"2001","unstructured":"Rompalo AM, Joesoef MR, O\u2019Donnell JA, Augenbraun M, Brady W, Radolf JD, Johnson R, Rolfs RT, Syphilis, Group HIVS. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis. 2001;28:158\u201365.","journal-title":"Sex Transm Dis"},{"key":"216_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1071\/SH14168","volume":"12","author":"FV Cresswell","year":"2015","unstructured":"Cresswell FV, Fisher M. Management of syphilis in HIV-positive individuals. Sex Health. 2015;12:135\u201340.","journal-title":"Sex Health"},{"key":"216_CR21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QCO.0000000000000132","volume":"28","author":"D Lawrence","year":"2015","unstructured":"Lawrence D, Cresswell F, Whetham J, Fisher M. Syphilis treatment in the presence of HIV: the debate goes on. Curr Opin Infect Dis. 2015;28:44\u201352.","journal-title":"Curr Opin Infect Dis"},{"key":"216_CR22","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1128\/JCM.01989-13","volume":"51","author":"J Dumaresq","year":"2013","unstructured":"Dumaresq J, Langevin S, Gagnon S, Serhir B, Deligne B, Tremblay C, Tsang RS, Fortin C, Coutlee F, Roger M. Clinical prediction and diagnosis of neurosyphilis in HIV-infected patients with early Syphilis. J Clin Microbiol. 2013;51:4060\u20136.","journal-title":"J Clin Microbiol"},{"key":"216_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.15585\/mmwr.mm6543a2","volume":"65","author":"SE Oliver","year":"2016","unstructured":"Oliver SE, Aubin M, Atwell L, Matthias J, Cope A, Mobley V, Goode A, Minnerly S, Stoltey J, Bauer HM, et al. Ocular syphilis\u2014eight jurisdictions, United States, 2014\u20132015. MMWR Morb Mortal Wkly Rep. 2016;65:1185\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"216_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/sti.2010.043893","volume":"87","author":"LJ Blank","year":"2011","unstructured":"Blank LJ, Rompalo AM, Erbelding EJ, Zenilman JM, Ghanem KG. Treatment of syphilis in HIV-infected subjects: a systematic review of the literature. Sex Transm Infect. 2011;87:9\u201316.","journal-title":"Sex Transm Infect"},{"key":"216_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/OLQ.0000000000000216","volume":"42","author":"RK Bolan","year":"2015","unstructured":"Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015;42:98\u2013103.","journal-title":"Sex Transm Dis"},{"key":"216_CR26","unstructured":"Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Meyer L. On demand post exposure prophylaxis with doxycycline for MSM enrolled in a prep trial [abstract]. In: Conference on retroviruses and opportunistic infections. Seattle, Washington; 2017."},{"key":"216_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362\u201371.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"216_CR28","unstructured":"US Department of Health and Human Services. Considerations for antiretroviral use in patients with coinfections. In: guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Washington DC: National Institute of Health; 2017."},{"key":"216_CR29","unstructured":"HCV Guidance. Recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org\/ . Accessed 2017."},{"key":"216_CR30","unstructured":"Hirnschall G. The WHO draft global strategy [abstract]. In: The international liver congress. Barcelona, Spain; 2016."},{"key":"216_CR31","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"216_CR32","unstructured":"Naggie S, Cooper C, Saag M, Yang J, Stamm L, PS. P, McHutchison J, Dieterich D, Sulkowski M. Ledipasvir\/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 [abstract]. In: Conference on retroviruses and opportunistic infections. Seattle, Washington; 2015."},{"key":"216_CR33","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594\u2013603.","journal-title":"N Engl J Med"},{"key":"216_CR34","unstructured":"Wyles D, Ruane P, Sulkowski M, Dieterich D, Luetkemeyer AF, Morgan TR, Sherman KE, Liu Z, Noviello S, Ackerman P. Daclatasvir in combination with sofosbuvir for HIV\/HCV coinfection: ALLY-2 study [abstract]. In: Conference on retroviruses and opportunistic infections. Seattle, Washington; 2015."},{"key":"216_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, et al. Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1\u201313.","journal-title":"Ann Intern Med"},{"key":"216_CR36","doi-asserted-by":"crossref","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag M, Zamor P, Orkin C, et al. C-edge co-infected phase 3 study of grazoprevir\/elbasvir in patients with HCV\/HIV [abstract]. In: The international liver congress. Barcelona, Spain; 2015.","DOI":"10.1016\/S0168-8278(15)31089-8"},{"key":"216_CR37","doi-asserted-by":"crossref","unstructured":"Poordad F, Lawitz E, Gutierrez J, Evans B, Howe A, Feng H, Li J, Hwang P, Robertson M, Wahl J, et al. C-swift: Grazoprevir\/elbasvir\u2009+\u2009sofosbuvir in cirrhotic and noncirrhotic treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8\u00a0weeks and genotype 3 infection for durations of 8 or 12\u00a0weeks [abstract]. In: The international liver congress. Barcelona, Spain; 2015.","DOI":"10.1016\/S0168-8278(15)30013-1"},{"key":"216_CR38","doi-asserted-by":"crossref","unstructured":"Wyles D, N B, Kottilil S, Daar E, Workowski K, Luetkemeyer A, Adeyemi O, Ruane P, Doehle B, Huang K, et al. Sofosbuvir\/Velpatasvir fixed dose combination for 12\u00a0weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study [abstract]. In: The international liver congress. Barcelona, Spain; 2016.","DOI":"10.1016\/S0168-8278(16)00129-X"},{"key":"216_CR39","doi-asserted-by":"crossref","unstructured":"Rockstroh J, Lacombe K, Viani R, Orkin C, Wyles D, Luetkemeyer A, Soto-Malave R, Flisiak R, Bhagani S, Sherman K, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study [abstract]. In: IAS conference on HIV science; 2017.","DOI":"10.1016\/S0168-8278(17)30467-1"},{"key":"216_CR40","unstructured":"The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia. In: Hepatitis B and C in Australia annual surveillance report supplement 2017. UNSW Sydney, Sydney NSW 2052; 2017."},{"key":"216_CR41","doi-asserted-by":"crossref","unstructured":"Martinello M, Dore G, Bopage R, Finlayson R, Baker D, Bloch M, Filep E, Skurowski J, Lin L, Lamoury F, et al. Moving towards HCV elimination in HIV\/HCV co-infection in Australia following universal access to interferon-free therapy. In: Australiasian viral hepatitis elimination conference. Cairns, Australia 2017.","DOI":"10.1016\/S2055-6640(20)30890-6"},{"key":"216_CR42","doi-asserted-by":"crossref","unstructured":"Martinello M, Dore G, Bopage R, Finlayson R, Baker D, Bloch M, Wilcox A, Filep E, Hellard M, Matthews G. DAA treatment scale-up in HIV\/HCV co-infection: characterising a population at risk for reinfection [abstract]. In: The international liver congress. Amsterdam, The Netherlands; 2017.","DOI":"10.1016\/S0168-8278(17)31388-0"},{"key":"216_CR43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/cid\/ciq200","volume":"52","author":"GV Matthews","year":"2011","unstructured":"Matthews GV, Pham ST, Hellard M, Grebely J, Zhang L, Oon A, Marks P, van Beek I, Rawlinson W, Kaldor JM, et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis. 2011;52:803\u201311.","journal-title":"Clin Infect Dis"},{"key":"216_CR44","unstructured":"Australian STI management guidelines for use in primary care. http:\/\/www.sti.guidelines.org.au\/ . Accessed 2017."},{"key":"216_CR45","first-page":"E137","volume":"41","author":"MM Lahra","year":"2017","unstructured":"Lahra MM, Enriquez RP, National Neisseria N. Australian Gonococcal Surveillance Programme annual report, 2015. Commun Dis Intell Q Rep. 2017;41:E137\u201345.","journal-title":"Commun Dis Intell Q Rep"},{"key":"216_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1099\/jmm.0.007641-0","volume":"58","author":"J Tapsall","year":"2009","unstructured":"Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol. 2009;58:683\u20137.","journal-title":"J Med Microbiol"},{"key":"216_CR47","doi-asserted-by":"publisher","first-page":"20323","DOI":"10.2807\/ese.17.47.20323-en","volume":"17","author":"M Unemo","year":"2012","unstructured":"Unemo M, European STIGEB. The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults recommends dual antimicrobial therapy. Euro Surveill. 2012;17:20323.","journal-title":"Euro Surveill"},{"key":"216_CR48","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/jac\/dkt017","volume":"68","author":"YM Chen","year":"2013","unstructured":"Chen YM, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G. Failure of 500\u00a0mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother. 2013;68:1445\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"216_CR49","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1071\/SH13077","volume":"10","author":"PJ Read","year":"2013","unstructured":"Read PJ, Limnios EA, McNulty A, Whiley D, Lahra MM. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500\u00a0mg ceftriaxone in Sydney, Australia. Sex Health. 2013;10:460\u20132.","journal-title":"Sex Health"},{"key":"216_CR50","doi-asserted-by":"publisher","first-page":"20862","DOI":"10.2807\/1560-7917.ES2014.19.30.20862","volume":"19","author":"D Golparian","year":"2014","unstructured":"Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, Fredlund H, Unemo M. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500\u00a0mg) or cefotaxime (500\u00a0mg), Sweden, 2013 and 2014. Euro Surveill. 2014;19:20862.","journal-title":"Euro Surveill"},{"key":"216_CR51","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1512757","volume":"374","author":"H Fifer","year":"2016","unstructured":"Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, Unemo M. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med. 2016;374:2504\u20136.","journal-title":"N Engl J Med"},{"key":"216_CR52","first-page":"19998","volume":"16","author":"M Unemo","year":"2011","unstructured":"Unemo M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 2011;16:19998.","journal-title":"Euro Surveill"},{"key":"216_CR53","first-page":"19833","volume":"16","author":"CA Ison","year":"2011","unstructured":"Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011;16:19833.","journal-title":"Euro Surveill"},{"key":"216_CR54","unstructured":"Public Health England. Outbreak of high level azithromycin resistant gonorrhoea in England: an update. In: Weekly report (Health Protection Report ed.) vol. 10; 2016."},{"key":"216_CR55","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/cid\/cix485","volume":"65","author":"AR Katz","year":"2017","unstructured":"Katz AR, Komeya AY, Kirkcaldy RD, Whelen AC, Soge OO, Papp JR, Kersh EN, Wasserman GM, O\u2019Connor NP, O\u2019Brien PS, et al. Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016. Clin Infect Dis. 2017;65:918\u201323.","journal-title":"Clin Infect Dis"},{"key":"216_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1473-3099(17)30007-5","volume":"17","author":"MM Lahra","year":"2017","unstructured":"Lahra MM, Ward A, Trembizki E, Hermanson J, Clements E, Lawrence A, Whiley D. Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in South Australia. Lancet Infect Dis. 2017;17:133\u20134.","journal-title":"Lancet Infect Dis"},{"key":"216_CR57","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cmi.2015.11.016","volume":"22","author":"M Bissessor","year":"2016","unstructured":"Bissessor M, Tabrizi SN, Bradshaw CS, Fairley CK, Hocking JS, Garland SM, Twin J, Poljak M, Peel J, Chen MY. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin Microbiol Infect. 2016;22:260\u20135.","journal-title":"Clin Microbiol Infect"},{"key":"216_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/sti.2009.038190","volume":"86","author":"S Soni","year":"2010","unstructured":"Soni S, Alexander S, Verlander N, Saunders P, Richardson D, Fisher M, Ison C. The prevalence of urethral and rectal Mycoplasma genitalium and its associations in men who have sex with men attending a genitourinary medicine clinic. Sex Transm Infect. 2010;86:21\u20134.","journal-title":"Sex Transm Infect"},{"key":"216_CR59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/OLQ.0b013e318177ec39","volume":"35","author":"SC Francis","year":"2008","unstructured":"Francis SC, Kent CK, Klausner JD, Rauch L, Kohn R, Hardick A, Gaydos CA. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005\u20132006. Sex Transm Dis. 2008;35:797\u2013800.","journal-title":"Sex Transm Dis"},{"key":"216_CR60","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1128\/CMR.00006-11","volume":"24","author":"D Taylor-Robinson","year":"2011","unstructured":"Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clin Microbiol Rev. 2011;24:498\u2013514.","journal-title":"Clin Microbiol Rev"},{"key":"216_CR61","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/jdv.13849","volume":"30","author":"JS Jensen","year":"2016","unstructured":"Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016;30:1650\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"216_CR62","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/cid\/ciu1162","volume":"60","author":"M Bissessor","year":"2015","unstructured":"Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, Vodstrcil LA, Jensen JS, Hocking JS, Garland SM, Bradshaw CS. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60:1228\u201336.","journal-title":"Clin Infect Dis"},{"key":"216_CR63","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/cid\/ciw719","volume":"64","author":"TR Read","year":"2017","unstructured":"Read TR, Fairley CK, Tabrizi SN, Bissessor M, Vodstrcil L, Chow EP, Grant M, Danielewski J, Garland SM, Hocking JS, et al. Azithromycin 1.5\u00a0g over 5 days compared to 1\u00a0g single dose in urethral Mycoplasma genitalium: impact on treatment outcome and resistance. Clin Infect Dis. 2017;64:250\u20136.","journal-title":"Clin Infect Dis"},{"key":"216_CR64","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1093\/jac\/dku164","volume":"69","author":"M Kikuchi","year":"2014","unstructured":"Kikuchi M, Ito S, Yasuda M, Tsuchiya T, Hatazaki K, Takanashi M, Ezaki T, Deguchi T. Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan. J Antimicrob Chemother. 2014;69:2376\u201382.","journal-title":"J Antimicrob Chemother"},{"key":"216_CR65","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3201\/eid2305.161745","volume":"23","author":"GL Murray","year":"2017","unstructured":"Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM, Jensen JS, Fairley CK, Tabrizi SN. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis. 2017;23:809\u201312.","journal-title":"Emerg Infect Dis"},{"key":"216_CR66","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3201\/eid2402.170902","volume":"24","author":"TRH Read","year":"2018","unstructured":"Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, Murray GL, Chow EPF, Worthington K, Garland SM, et al. Use of pristinamycin for macrolide-resistant Mycoplasma genitalium infection. Emerg Infect Dis. 2018;24:328\u201335.","journal-title":"Emerg Infect Dis"},{"key":"216_CR67","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3201\/eid2311.170998","volume":"23","author":"JB Slifirski","year":"2017","unstructured":"Slifirski JB, Vodstrcil LA, Fairley CK, Ong JJ, Chow EPF, Chen MY, Read TRH, Bradshaw CS. Mycoplasma genitalium infection in adults reporting sexual contact with infected partners, Australia, 2008\u20132016. Emerg Infect Dis. 2017;23:1826\u201333.","journal-title":"Emerg Infect Dis"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-018-0216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-018-0216-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-018-0216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T22:51:56Z","timestamp":1605739916000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-018-0216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1186\/s12981-018-0216-9","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"8 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"28"}}